University of Utah
Pharmacy in Salt Lake City, UT

2013009, Apr 25, 2013

Oct 19, 2012

13/656565

University of Utah Research Foundation - Salt Lake City UT, US
Ye Zhang - Salt Lake City UT, US
Rujie Sun - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

H01L 31/0352, H01L 33/06

257 28, 257E33005, 257E31037

An electrical device comprising (A) a substrate having a surface and (B) a nanohole superlattice superimposed on a portion of the surface is provided. The nanohole superlattice comprises a plurality of sheets having an array of holes defined therein. The array of holes is characterized by a band gap or band gap range. The plurality of sheets forms a first edge and a second edge. A first lead comprising a first electrically conductive material forms a first junction with the first edge. A second lead comprising a second electrically conductive material forms a second junction with the second edge. The first junction is a Schottky barrier with respect to a carrier. In some instances a metal protective coating covers all or a portion of a surface of the first lead. In some instances, the first lead comprises titanium, the second lead comprises palladium, and the metal protective coating comprises gold.

2013013, May 23, 2013

Jan 11, 2013

13/739800

University of Utah Research Foundation - Salt Lake City UT, US
Richard Rabbitt - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

C12Q 1/02

435 29

A method for triggering cellular exocytosis events and measuring quantal release of electroactive chemicals is disclosed. A method can include flowing a cell through a single cell channel having a pair of electrodes oriented to direct current through the cell at a stimulation location along the single cell channel. The pair of electrodes include a working electrode, a counter electrode and an optional reference electrode. The single cell channel has dimensions which provide direct contact of the cell with walls of the single cell channel sufficient to substantially reduce or eliminate shunt paths around the cell at the stimulation location. The cell can be exposed to an electric field at the stimulation location using the pair of electrodes sufficient to trigger exocytosis. Changes in current due to exocytosis processes appear as spikes that can be correlated with a quanta of the electroactive chemicals which are released during exocytosis.

2013016, Jun 27, 2013

Sep 17, 2012

13/621789

University of Utah - Salt Lake City UT, US
University of Utah Research Foundation - Salt Lake City UT, US

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
UNIVERSITY OF UTAH - Salt Lake City UT

C12Q 1/68

435 611, 435 612, 435 792, 436501

The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.

2013018, Jul 18, 2013

Nov 14, 2012

13/676980

University of Utah Research Foundation - Salt Lake City UT, US
Alan L. Rockwood - Riverton UT, US
A. Wayne Meikle - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

G01N 33/53

436501, 422430

The present invention provides methods, compositions, and kits associated with analyzing, enriching, and/or isolating a biomarker or analyte in a biological sample. In one aspect, for example, a method for determining a concentration of a biomarker in a biological sample can include binding any unbound biomarker with an antibody specific for the biomarker to form antibody-bound biomarker, enriching the antibody-bound biomarker and any endogenous autoantibody-bound biomarker to form an enriched fraction, identifying the biomarker in the enriched fraction, and determining the concentration of the biomarker in the biological sample. In one aspect, the concentration of the biomarker is derived from initially unbound biomarker and autoantibody-bound biomarker in the biological sample.

2013019, Jul 25, 2013

Mar 10, 2013

13/792181

University of Utah Research Foundation - Salt Lake City UT, US
Erik Jorgensen - Salt Lake City UT, US
Paola Nix - Salt Lake City UT, US
Marc Hammarlund - Hamden CT, US

University of Utah Research Foundation - Salt Lake City UT

A61K 31/713, A61K 31/7088

514 44 A, 514 44 R, 536 232, 536 245, 506 10

Disclosed are compositions and methods for treating neurodegenerative disease.

2013020, Aug 8, 2013

Mar 14, 2013

13/828308

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT, US
Randall J. Olson - Salt Lake City UT, US

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

A61F 2/16

623 634

A vision correction system comprising an intraocular lens having a lens body and one or more haptics is provided. The lens body may be configured to be positioned posteriorly to an iris of an eye and may have a convex anterior surface, a concave posterior surface, and a circumferential edge having a rounded anterior portion and a rounded posterior portion. Haptics may extend at an anterior angle from the lens body and be configured to contact the ciliary sulcus of an eye. The haptics and/or hydrophobic forces between this lens body and a second intraocular lens may secure the lens body in the eye in a relatively fixed position and prevent rotation of the lens over time.

2013010, May 2, 2013

Dec 17, 2012

13/717264

University of Utah Research Foundation - Salt Lake City UT, US
Fenghuang ZHAN - Salt Lake City UT, US
Guido TRICOT - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

C12Q 1/68, G01N 33/68

435 611, 435 723, 435 614, 435 612

Disclosed herein are diagnostic and prognostic methods for determining the overall survival, and therapeutic regimes, for multiple myeloma patients. The methods involve the detection of PTHR1 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring treatment of patients having or suspected of having multiple myeloma. The disclosure also relates to proteasome inhibitors and other activators of PTHR1, for the treatment of multiple myeloma.

2013012, May 16, 2013

Dec 21, 2012

13/725360

University of Utah Research Foundation - Salt Lake City UT, US
Carlos H. Mastrangelo - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

G01F 1/74, G01N 21/55, C23C 16/01

428402, 216 56, 356442, 2524081

Microparticles () and systems and methods for measuring characteristics of fluid flow using the microparticles are described. The microparticle () can include at least one flexible wall () which can deflect when an outer pressure on an outer side of the wall is different than an inner pressure on an inner side of the wall. The microparticle () can also include a void () enclosed by the at least one wall () and can change shape as the wall () deflects.

2013012, May 16, 2013

Oct 16, 2012

13/653311

University of Utah Research Foundation - Salt Lake City UT, US
Douglas G. KONDO - Salt Lake City UT, US

UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT

A61B 5/055

600410, 514789

Described herein are systems and methods of identifying bipolar disorder in a person. One such method includes acquiring P spectroscopic imaging data from a region of interest in a brain of the person and subsequently analyzing the P spectroscopic imaging data to obtain a signal intensity and a concentration for one or more phosphorus metabolites. A reduced concentration the one or more phosphorus metabolites, such as inorganic phosphate, in the brain can indicate bipolar disorder in the person. Frontal lobe inorganic phosphate concentration in medication-free adolescents can indicate bipolar depression.

2013012, May 23, 2013

Jan 16, 2013

13/742877

University of Utah Research Foundation - Salt Lake City UT, US
Meredith C. Roberts - Salt Lake City UT, US
Patrick F. Kiser - Salt Lake City UT, US
Julie I. Jay - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

C08F 30/06, A61K 47/32

424400, 526239, 5147724, 4241301

Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described are methods of making and using such polymeric compositions.